Koers Oasmia Pharmaceutical AB NORDIC GROWTH MARKET
Aandelen
OASM
SE0000722365
Farmaceutische producten
Omzet 2022 | 3,04 mln. 287K 265K | Omzet 2023 | 6,61 mln. 624K 576K | Marktkapitalisatie | 219 mln. 20,71 mln. 19,09 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -357 mln. -33,71 mln. -31,08 mln. | Nettowinst (verlies) 2023 | -129 mln. -12,18 mln. -11,23 mln. | EV/omzet 2022 | 32,6 x |
Nettoliquiditeiten 2022 | 134 mln. 12,69 mln. 11,7 mln. | Nettoliquiditeiten 2023 | 77,04 mln. 7,28 mln. 6,71 mln. | EV/omzet 2023 | 21,5 x |
K/w-verhouding 2022 |
-0,6
x | K/w-verhouding 2023 |
-1,7
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 61,42% |
Recentste transcriptie over Oasmia Pharmaceutical AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-23 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 01-12-20 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-03-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 44 | 19-03-19 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 26-09-19 |
Pål Ryfors
BRD | Director/Board Member | 41 | 25-05-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,59% | 727 mld. | |
-7,89% | 347 mld. | |
+15,66% | 319 mld. | |
+0,24% | 274 mld. | |
+13,47% | 238 mld. | |
+7,35% | 204 mld. | |
-6,42% | 203 mld. | |
+4,23% | 161 mld. | |
-1,70% | 160 mld. |